Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N S Nicholson

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1991
Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749)N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Medicinal Research Reviews|April 13, 2001
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonistN S Nicholson, N A Abood, S G Panzer-Knodle, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1991
Antiplatelet and antithrombotic effects of platelet glycoprotein IIb/IIIa (GPIIb/IIIa) inhibition by arginine-glycine-aspartic acid-serine (RGDS) and arginine-glycine-aspartic acid (RGD) (O-me)Y (SC-46749)N S Nicholson, S G Panzer-Knodle, A K Salyers, et al.
Medicinal Research Reviews|April 13, 2001
Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonistN S Nicholson, N A Abood, S G Panzer-Knodle, et al.
Pageof 3